Open AccessTreatment of Genital, Scalp and Face Psoriasis with Risankizumab
Author(s) -
Okita Al
Publication year - 2021
Language(s) - English
DOI - 10.24966/cdt-8771/100078
Subject(s) - psoriasis , scalp , medicine , dermatology , embarrassment , sex organ , disease , interleukin 23 , pathology , immunology , interleukin 17 , immune system , psychology , social psychology , biology , genetics
Psoriasis affecting the face, scalp, hands, feet, nail and genitals may cause disproportional impact on quality of life despite the small surface area compromised. Genital psoriasis can affect 33 to 63% of psoriasis patients at any time during their lives. Even though GenPs is relatively common, these lesions may be under-reported and under diagnosed because of embarrassment of patients, unfamiliarity with the disease or concerns about having a sexually transmitted disease. Several effective treatments have been reported for plaque psoriasis, however there are few studies and reports regarding GenPs treatment. We report here a case of successful treatment of a patient with genital, face and scalp psoriasis with risankizumab, an anti-IL23 drug